Now showing items 136-155 of 1086

    • Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. 

      Saya, S; Killick, E; Thomas, S; Taylor, N; Bancroft, EK; Rothwell, J; Benafif, S; Dias, A; Mikropoulos, C; Pope, J; Chamberlain, A; Gunapala, R; SIGNIFY Study Steering Committee; Izatt, L; Side, L; Walker, L; Tomkins, S; Cook, J; Barwell, J; Wiles, V; Limb, L; Eccles, D; Leach, MO; Shanley, S; Gilbert, FJ; Hanson, H; Gallagher, D; Rajashanker, B; Whitehouse, RW; Koh, D-M; Sohaib, SA; Evans, DG; Eeles, RA (2017-07)
      In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study sought to ...
    • Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. 

      Ballinger, ML; Best, A; Mai, PL; Khincha, PP; Loud, JT; Peters, JA; Achatz, MI; Chojniak, R; Balieiro da Costa, A; Santiago, KM; Garber, J; O'Neill, AF; Eeles, RA; Evans, DG; Bleiker, E; Sonke, GS; Ruijs, M; Loo, C; Schiffman, J; Naumer, A; Kohlmann, W; Strong, LC; Bojadzieva, J; Malkin, D; Rednam, SP; Stoffel, EM; Koeppe, E; Weitzel, JN; Slavin, TP; Nehoray, B; Robson, M; Walsh, M; Manelli, L; Villani, A; Thomas, DM; Savage, SA (2017-12)
      Importance Guidelines for clinical management in Li-Fraumeni syndrome, a multiple-organ cancer predisposition condition, are limited. Whole-body magnetic resonance imaging (WBMRI) may play a role in surveillance of this ...
    • Beam modeling and VMAT performance with the Agility 160-leaf multileaf collimator. 

      Bedford, JL; Thomas, MDR; Smyth, G (2013-05-06)
      The Agility multileaf collimator (Elekta AB, Stockholm, Sweden) has 160 leaves of projected width 0.5 cm at the isocenter, with maximum leaf speed 3.5 cms-1. These characteristics promise to facilitate fast and accurate ...
    • Beam selection for stereotactic ablative radiotherapy using Cyberknife with multileaf collimation. 

      Bedford, JL; Ziegenhein, P; Nill, S; Oelfke, U (2019-02)
      The Cyberknife system (Accuray Inc., Sunnyvale, CA) enables radiotherapy using stereotactic ablative body radiotherapy (SABR) with a large number of non-coplanar beam orientations. Recently, a multileaf collimator has also ...
    • Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. 

      Winfield, JM; Wakefield, JC; Brenton, JD; AbdulJabbar, K; Savio, A; Freeman, S; Pace, E; Lutchman-Singh, K; Vroobel, KM; Yuan, Y; Banerjee, S; Porta, N; Ahmed Raza, SE; deSouza, NM (2021-01-04)
      Background Diffusion-weighted magnetic resonance imaging (DW-MRI) potentially interrogates site-specific response to neoadjuvant chemotherapy (NAC) in epithelial ovarian cancer (EOC).Methods Participants with newly diagnosed ...
    • Blood lipids and prostate cancer: a Mendelian randomization analysis. 

      Bull, CJ; Bonilla, C; Holly, JMP; Perks, CM; Davies, N; Haycock, P; Yu, OHY; Richards, JB; Eeles, R; Easton, D; Kote-Jarai, Z; Amin Al Olama, A; Benlloch, S; Muir, K; Giles, GG; MacInnis, RJ; Wiklund, F; Gronberg, H; Haiman, CA; Schleutker, J; Nordestgaard, BG; Travis, RC; Neal, D; Pashayan, N; Khaw, K-T; Stanford, JL; Blot, WJ; Thibodeau, S; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Brenner, H; Park, J; Kaneva, R; Batra, J; Teixeira, MR; Micheal, A; Pandha, H; Smith, GD; Lewis, SJ; Martin, RM; PRACTICAL consortium (2016-06)
      Genetic risk scores were used as unconfounded instruments for specific lipid traits (Mendelian randomization) to assess whether circulating lipids causally influence prostate cancer risk. Data from 22,249 prostate cancer ...
    • Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. 

      Welsh, L; Panek, R; Riddell, A; Wong, K; Leach, MO; Tavassoli, M; Rahman, D; Schmidt, M; Hurley, T; Grove, L; Richards, T; Koh, D-M; Nutting, C; Harrington, K; Newbold, K; Bhide, S (2017-01)
      Background Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radical chemo-radiation (CRT) frequently receive transfusion with packed red cells (PRCT) during radiotherapy on the basis that PRCT increases ...
    • Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. 

      Denis-Bacelar, AM; Chittenden, SJ; McCready, VR; Divoli, A; Dearnaley, DP; O'Sullivan, JM; Johnson, B; Flux, GD (2018-04)
      OBJECTIVE:The aim of this study was to calculate the range of absorbed doses that could potentially be delivered by a variety of radiopharmaceuticals and typical fixed administered activities used for bone pain palliation ...
    • BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). 

      Kelly, JD; Tan, WS; Porta, N; Mostafid, H; Huddart, R; Protheroe, A; Bogle, R; Blazeby, J; Palmer, A; Cresswell, J; Johnson, M; Brough, R; Madaan, S; Andrews, S; Cruickshank, C; Burnett, S; Maynard, L; Hall, E; BOXIT Investigators (2019-04)
      Background Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy.Objective To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk of ...
    • Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. 

      Nichols, HB; Schoemaker, MJ; Cai, J; Xu, J; Wright, LB; Brook, MN; Jones, ME; Adami, H-O; Baglietto, L; Bertrand, KA; Blot, WJ; Boutron-Ruault, M-C; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Gram, IT; Hankinson, SE; Hoffman-Bolton, J; Kaaks, R; Key, TJ; Kitahara, CM; Larsson, SC; Linet, M; Merritt, MA; Milne, RL; Pala, V; Palmer, JR; Peeters, PH; Riboli, E; Sund, M; Tamimi, RM; Tjønneland, A; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Wolk, A; Zheng, W; Weinberg, CR; Swerdlow, AJ; Sandler, DP (2019-01)
      Background Parity is widely recognized as protective for breast cancer, but breast cancer risk may be increased shortly after childbirth. Whether this risk varies with breastfeeding, family history of breast cancer, or ...
    • Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent. 

      Johnson, L; O'Donoghue, JM; McLean, N; Turton, P; Khan, AA; Turner, SD; Lennard, A; Collis, N; Butterworth, M; Gui, G; Bristol, J; Hurren, J; Smith, S; Grover, K; Spyrou, G; Krupa, K; Azmy, IA; Young, IE; Staiano, JJ; Khalil, H; MacNeill, FA (2017-08)
      Background Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare, Non-Hodgkin lymphoma arising in the capsule of breast implants. BIA-ALCL presents as a recurrent effusion and/or mass. Tumours exhibit ...
    • Breast MRI segmentation for density estimation: Do different methods give the same results and how much do differences matter? 

      Doran, SJ; Hipwell, JH; Denholm, R; Eiben, B; Busana, M; Hawkes, DJ; Leach, MO; Silva, IDS (2017-09)
      Purpose To compare two methods of automatic breast segmentation with each other and with manual segmentation in a large subject cohort. To discuss the factors involved in selecting the most appropriate algorithm for automatic ...
    • Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. 

      Zuber, V; Bettella, F; Witoelar, A; PRACTICAL Consortium; CRUK GWAS; BCAC Consortium; TRICL Consortium; Andreassen, OA; Mills, IG; Urbanucci, A (2017-03-31)
      Background Epigenetic information can be used to identify clinically relevant genomic variants single nucleotide polymorphisms (SNPs) of functional importance in cancer development. Super-enhancers are cell-specific DNA ...
    • Calculation of absorbed dose in radiotherapy by solution of the linear Boltzmann transport equations. 

      Bedford, JL (2019-01-10)
      Over the last decade, dose calculations which solve the linear Boltzmann transport equations have been introduced into clinical practice and are now in widespread use. However, knowledge in the radiotherapy community ...
    • Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer? 

      Bhattacharya, IS; Kirby, AM; Bliss, JM; Coles, CE (2018-03)
      Adjuvant radiotherapy after breast-conserving surgery has been an important component of the standard of care for early breast cancer. Improvements in breast cancer care have resulted in a substantial reduction in local ...
    • Can patient decision aids reduce decisional conflict in a de-escalation of breast radiotherapy clinical trial? The PRIMETIME Study Within a Trial implemented using a cluster stepped-wedge trial design. 

      Bhattacharya, IS; Haviland, JS; Turner, L; Stobart, H; Balasopoulou, A; Stones, L; Kirby, AM; Kirwan, CC; Coles, CE; Bliss, JM; PRIMETIME Trialists (2021-06-14)
      Background For patients with early breast cancer considered at very-low risk of local relapse, risks of radiotherapy may outweigh the benefits. Decisions regarding treatment omission can lead to patient uncertainty (decisional ...
    • Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. 

      Bhattacharya, IS; Haviland, JS; Hopwood, P; Coles, CE; Yarnold, JR; Bliss, JM; Kirby, AM; IMPORT Trialists (2019-05)
      Background In an era of low local relapse rates after adjuvant breast radiotherapy, risks of late normal-tissue effects (NTE) need to be balanced against risk of relapse. NTE are assessed using patient-reported outcome ...
    • Cancer heterogeneity and imaging. 

      O'Connor, JPB (2017-04)
      There is interest in identifying and quantifying tumor heterogeneity at the genomic, tissue pathology and clinical imaging scales, as this may help better understand tumor biology and may yield useful biomarkers for guiding ...
    • Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. 

      Peterlongo, P; Chang-Claude, J; Moysich, KB; Rudolph, A; Schmutzler, RK; Simard, J; Soucy, P; Eeles, RA; Easton, DF; Hamann, U; Wilkening, S; Chen, B; Rookus, MA; Schmidt, MK; van der Baan, FH; Spurdle, AB; Walker, LC; Lose, F; Maia, A-T; Montagna, M; Matricardi, L; Lubinski, J; Jakubowska, A; Gómez Garcia, EB; Olopade, OI; Nussbaum, RL; Nathanson, KL; Domchek, SM; Rebbeck, TR; Arun, BK; Karlan, BY; Orsulic, S; Lester, J; Chung, WK; Miron, A; Southey, MC; Goldgar, DE; Buys, SS; Janavicius, R; Dorfling, CM; van Rensburg, EJ; Ding, YC; Neuhausen, SL; Hansen, TVO; Gerdes, A-M; Ejlertsen, B; Jønson, L; Osorio, A; Martínez-Bouzas, C; Benitez, J; Conway, EE; Blazer, KR; Weitzel, JN; Manoukian, S; Peissel, B; Zaffaroni, D; Scuvera, G; Barile, M; Ficarazzi, F; Mariette, F; Fortuzzi, S; Viel, A; Giannini, G; Papi, L; Martayan, A; Tibiletti, MG; Radice, P; Vratimos, A; Fostira, F; Garber, JE; Donaldson, A; Brewer, C; Foo, C; Evans, DGR; Frost, D; Eccles, D; Brady, A; Cook, J; Tischkowitz, M; Adlard, J; Barwell, J; Walker, L; Izatt, L; Side, LE; Kennedy, MJ; Rogers, MT; Porteous, ME; Morrison, PJ; Platte, R; Davidson, R; Hodgson, SV; Ellis, S; Cole, T; EMBRACE; Godwin, AK; Claes, K; Van Maerken, T; Meindl, A; Gehrig, A; Sutter, C; Engel, C; Niederacher, D; Steinemann, D; Plendl, H; Kast, K; Rhiem, K; Ditsch, N; Arnold, N; Varon-Mateeva, R; Wappenschmidt, B; Wang-Gohrke, S; Bressac-de Paillerets, B; Buecher, B; Delnatte, C; Houdayer, C; Stoppa-Lyonnet, D; Damiola, F; Coupier, I; Barjhoux, L; Venat-Bouvet, L; Golmard, L; Boutry-Kryza, N; Sinilnikova, OM; Caron, O; Pujol, P; Mazoyer, S; Belotti, M; GEMO Study Collaborators; Piedmonte, M; Friedlander, ML; Rodriguez, GC; Copeland, LJ; de la Hoya, M; de la Hoya, M; Segura, PP; Nevanlinna, H; Aittomäki, K; van Os, TAM; Meijers-Heijboer, HEJ; van der Hout, AH; Vreeswijk, MPG; Hoogerbrugge, N; Ausems, MGEM; van Doorn, HC; Collée, JM; HEBON; Olah, E; Diez, O; Blanco, I; Lazaro, C; Brunet, J; Feliubadalo, L; Cybulski, C; Gronwald, J; Durda, K; Jaworska-Bieniek, K; Sukiennicki, G; Arason, A; Chiquette, J; Teixeira, MR; Olswold, C; Couch, FJ; Lindor, NM; Wang, X; Szabo, CI; Offit, K; Corines, M; Jacobs, L; Robson, ME; Zhang, L; Joseph, V; Joseph, V; Berger, A; Singer, CF; Rappaport, C; Kaulich, DG; Pfeiler, G; Tea, M-KM; Phelan, CM; Greene, MH; Mai, PL; Rennert, G; Mulligan, AM; Glendon, G; Tchatchou, S; Andrulis, IL; Toland, AE; Bojesen, A; Pedersen, IS; Thomassen, M; Jensen, UB; Laitman, Y; Rantala, J; von Wachenfeldt, A; Ehrencrona, H; Askmalm, MS; Borg, Å; Kuchenbaecker, KB; McGuffog, L; Barrowdale, D; Healey, S; Lee, A; Pharoah, PDP; Chenevix-Trench, G; KConFab Investigators; Antoniou, AC; Friedman, E (2015-01)
      Background BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation ...